Latest news with #diabetes
CBC
an hour ago
- Health
- CBC
What cheaper versions of Ozempic will mean for B.C.'s diabetics
In January 2026, the Canadian patent for Ozempic will expire, paving the way for cheap generic versions of the semaglutide injections that help regulate blood sugar levels and appetite. Dr. Tom Elliott, medical director at B.C. Diabetes, says that semaglutide injections have revolutionized his practice, and they are astonishingly effective.
Daily Mail
11 hours ago
- Health
- Daily Mail
Ozempic found to slash risk of disease affecting 6.7m Americans each year
Blockbuster weight loss drugs could slash the risk of developing memory-robbing dementia, a major study suggests. Researchers in Ireland analyzed clinical trials of nearly 165,000 taking drugs to lower their glucose (blood sugar) and treat diabetes. The team found most glucose-lowering treatments had no significant impact on dementia risk. However, people taking GLP-1 agonists like Ozempic and Wegovy were 45 percent less likely to develop dementia at some point in their lives than people on other drugs. While it's unclear exactly how the active ingredients in these drugs - most often semaglutide and tirzepatide - reduce the likelihood of dementia, the researchers believe they may lower inflammation in the brain. Neuroinflammation is thought to damage neurons and disrupt communications to part of the brain responsible for memory, triggering dementia symptoms. GLP-1 agonists may also reduce toxic amyloid and tau proteins, hallmarks of dementia. The team suspects GLP-1 agonists like Ozempic may help prevent both diabetes and dementia, both of which are on the rise in the US. Dr Catriona Reddin, senior study author and researcher at the University of Galway, said: 'This research represents a significant contribution to our understanding of how some diabetes medications may impact brain health. 'Diabetes is a known risk factor for dementia, but whether glucose-lowering therapies can help prevent cognitive decline has remained unclear. 'Our findings suggest that GLP-1 receptor agonists, in particular, may have a protective effect on brain health.' The study comes after a similar experiment from the University of Florida, which tracked 400,000 Americans on glucose-lowering drugs and found dementia risk was 33 percent lower for GLP-1 users compared to other interventions. Around 8million adults in the US have some form of dementia, and 500,000 are diagnosed every year. Meanwhile, one in eight US adults has reported taking Ozempic or similar medications at least once for diabetes or weight loss. In the new study, published in JAMA Neurology, researchers identified 26 studies that explored the relationship between GLP-1 agonist use and dementia. These included a total of 164,531 participants, most of whom (65 percent) were men. The average age was 64 with a follow-up time of 31 months. Studies included in the analysis were published between 2015 and 2024. Of the 26 in the review, 10 looked at the impact of GLP-1 agonists. The team suspected GLP-1 agonists may lower inflammation, which is a major driver of dementia. It's thought to activate the immune cells microglia and astrocytes in the brain, which damage neurons and disrupt the blood-brain barrier, the brain's protective layer. GLP-1 agonists have also been shown to lower blood pressure and protect blood vessels, reducing the risk of vascular dementia. A study published in April also found GLP-1s may stimulate neural growth in the hippocampus, an area of the brain responsible for learning and memory formation. However, this research is early. Professor Martin O'Donnell, Dean of the College of Medicine, Nursing and Health Sciences at University of Galway: 'Given the increasing prevalence of both diabetes and dementia, findings from this study have important public health implications for prevention of dementia.' Recent reports from the Alzheimer's Association report rates of Alzheimer's disease - the most common form of dementia - have risen 25 years in a row in the US. Diabetes, meanwhile, affects 12 percent of Americans - 38million. Reports published in 2022 suggest rates in the Americas have tripled in the last 30 years. There were several limitations to the new study, mainly including a lack of data on subtypes of dementia like vascular and Lewy body dementia.
Yahoo
13 hours ago
- Business
- Yahoo
Wave Life Sciences Unveils Promising Preclinical Data for Obesity Treatment WVE-007 at ADA Scientific Sessions
Wave Life Sciences Ltd. (NASDAQ:WVE) is one of the best low priced pharma stocks to buy now. From June 20 to 23, Wave Life Sciences presented preclinical data for WVE-007, which is its investigational GalNAc-siRNA targeting INHBE mRNA, at the American Diabetes Association's 85th Annual Scientific Sessions in Chicago. The oral presentation was delivered on June 21 and highlighted WVE-007 as a potential novel and distinct obesity treatment designed to induce healthy weight loss by reducing fat while preserving muscle mass. WVE-007 functions by silencing INHBE mRNA, which in turn reduces the production of Activin E protein. Activin E is a lipolysis suppressor that is upregulated in obesity. By inhibiting Activin E, WVE-007 promotes lipolysis, or fat breakdown. A biotechnology laboratory filled with computers and equipment to support research. Human genetics provides strong support for INHBE as a therapeutic target. Individuals with a protective loss-of-function variant in one copy of the INHBE gene exhibit a healthier cardiometabolic profile, which includes less abdominal fat, lower triglycerides, and reduced risk of type 2 diabetes/T2D and cardiovascular disease/CAD. These individuals also show favorable associations with liver traits, such as reductions in cT1 (reflecting liver inflammation and fibrosis) and ALT (reflecting liver damage), without impacting liver fat. Wave Life Sciences Ltd. (NASDAQ:WVE) is a clinical-stage biotechnology company that designs, develops, and commercializes ribonucleic acid/RNA medicines through PRISM, which is a discovery and drug development platform. While we acknowledge the potential of WVE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
National Post
14 hours ago
- Business
- National Post
Market to Grow by 12.1% to Reach $6.97 Billion this Year - Investment Opportunities to 2029
Article content DUBLIN — The 'Canada Diabetes Devices and Therapeutics Market Investment Opportunities – Q2 2025 Update' report has been added to offering. Article content The diabetes market in Canada is expected to grow by 12.1% on annual basis to reach US$6.97 billion in 2025. The diabetes market in the country has experienced robust growth during 2020-2024, achieving a CAGR of 12.9%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 10.0% during 2025-2029. By the end of 2029, the diabetes market is projected to expand from its 2024 value of USD 6.22 billion to approximately USD 11.37 billion. Article content This report provides a detailed data-centric analysis of the diabetes industry in Canada, covering market opportunities and analysis across a range of diagnosis and monitoring devices, therapeutics, domains. With over 50+ KPIs at the country level, this report provides a comprehensive understanding of diabetes market dynamics, market size and forecast, and market share statistics. Article content The diabetes devices and therapeutics market in Canada comprises established multinational firms and emerging domestic players. A structured healthcare system with defined reimbursement pathways supports traditional and digital solutions. The Canadian diabetes devices and therapeutics market is characterized by a blend of multinational leaders and emerging technology-driven entrants. Recent strategic partnerships, mergers, and acquisitions indicate a move toward more integrated care solutions. In the coming years, competitive dynamics are expected to intensify, driven by consolidation and a focused shift toward digital integration and regulatory compliance. Article content The Canadian market is experiencing significant shifts, with increased CGM adoption, digital integration, advanced therapeutic systems, and evolving regulatory support. These trends will intensify over the next 2-4 years, shaping clinical practices and reimbursement structures across provincial healthcare systems. Article content Expand Continuous Glucose Monitoring Usage Article content Canadian healthcare systems are broadening the use of continuous glucose monitoring (CGM) devices across several provinces. Provincial pilot programs in regions such as Ontario and British Columbia are incorporating CGM into routine diabetes care. Adjustments in provincial reimbursement policies and recent clinical studies from Canadian health agencies support wider CGM use. Recent publications have highlighted a shift in clinical practice toward data-driven patient monitoring. The adoption of CGM is expected to intensify as more provinces expand coverage and integrate real-time data into care protocols. Enhanced patient monitoring may improve diabetes management outcomes over the medium term. Article content Digital health platforms that support remote monitoring and telemedicine are increasingly integrated into diabetes management in Canada. Several regional healthcare systems have initiated digital dashboards to consolidate patient data for clinical decision-making. Government initiatives to improve telehealth services and recent shifts in healthcare delivery models are driving digital integration. Recent publications underscore provincial health ministries' investments in digital infrastructure. The integration of digital tools is projected to grow, supporting real-time care adjustments and enhanced data sharing among providers. This trend is expected to intensify as digital health reshapes chronic disease management. Article content Advance Therapeutic Delivery Systems Article content Advanced therapeutic devices such as smart insulin pens and connected insulin pumps are being tested in clinical settings across Canada. Pilot programs in select provinces have assessed these devices for precise dosing and improved treatment adherence. Recent technological improvements and research findings from Canadian institutions support the development of these systems. Funding and innovation incentives from provincial health programs are fostering the introduction of these therapeutic tools. Adoption will likely grow as clinical evidence and reimbursement models evolve, integrating these devices into standard practice. The trend is expected to intensify gradually, influencing treatment protocols in diabetes care. Article content Regulatory and Reimbursement Models Article content Regulatory bodies in Canada are updating guidelines and reimbursement policies to accommodate new diabetes devices and therapeutics. Recent policy documents have outlined pathways for including digital health and connected devices in public healthcare programs. Broader cost-containment strategies and ongoing evaluations of digital health effectiveness drive regulatory adjustments. Publications from provincial health ministries and Health Canada provide context for these evolving frameworks. Clearer regulatory and reimbursement models are anticipated to further support device integration and market expansion. These changes are expected to have a progressive impact, offering more defined channels for innovation in diabetes management. Article content Key Competitors and New Entrants Article content Several longstanding multinational companies hold significant market share. They offer a range of devices, from continuous monitoring systems to therapeutic delivery tools, and maintain strategic relationships with provincial healthcare agencies. New market entrants, including technology-focused startups, are introducing digital health solutions that target remote monitoring and data integration. Recent publications indicate that pilot programs in provinces allow these entrants to demonstrate value. Article content Recent publications detail partnerships where established companies collaborate with digital health startups to enhance device connectivity and patient data analytics. Mergers and acquisitions have been noted as firms consolidate technical expertise and broaden their market offerings within the Canadian context. These strategic developments reshape the market by promoting integrated care solutions and streamlined regulatory compliance. Collaborative efforts are aligning product innovation with provincial healthcare priorities. Article content Future Competitive Dynamics (2-4 Years) Article content The competitive landscape is expected to evolve as strategic partnerships and consolidation efforts deepen. Companies will likely increase investments in digital health integration, balancing established market leaders with nimble entrants. Over the next 2-4 years, market consolidation and technology-driven innovation are anticipated to further define competitive positioning, with clear implications for patient management strategies. Article content Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices Article content Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices Article content Self-Monitoring Blood Glucose Devices Continuous Blood Glucose Monitoring Devices Test Strips Lancets Article content Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices Article content Insulin Pumps Insulin Pens Insulin Syringes Article content Diabetes Devices and Therapeutics Market Share by Therapeutics Article content Oral Anti-Diabetic Drugs Insulin Non-Insulin Injectable Drugs Combination Drugs Article content Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs Article content Alpha-Glucosidase Inhibitors DPP-4 Inhibitors SGLT-2 Inhibitors Article content Diabetes Devices and Therapeutics Market Share by Insulin Article content Basal or Long-Acting Bolus or Fast-Acting Traditional Human Insulin Drugs Insulin Biosimilars Article content Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs Article content GLP-1 Receptor Agonists Amylin Analogue Article content Diabetes Devices and Therapeutics Market Share by Combination Drugs Article content Combination Insulin Oral Combination Article content Diabetes Devices and Therapeutics Market Share by Route of Administration Article content Subcutaneous Intravenous Others Article content Diabetes Devices and Therapeutics Market Share by Type of Diabetes Article content Type 1 Diabetes Type 2 Diabetes Article content Diabetes Devices and Therapeutics Market Share by Distribution Channels Article content Online Pharmacies Hospital Pharmacies Retail Pharmacies Article content Diabetes Devices and Therapeutics Market Share by End User Article content Hospitals Diabetes Clinics Homecare Article content Key Attributes: Article content Report Attribute Details No. of Pages 50 Forecast Period 2025 – 2029 Estimated Market Value (USD) in 2025 $7.77 Billion Forecasted Market Value (USD) by 2029 $11.37 Billion Compound Annual Growth Rate 10.0% Regions Covered Canada Article content For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Article content Article content Article content Article content Article content Contacts Article content Article content
BBC News
15 hours ago
- Health
- BBC News
Barbie with type 1 diabetes will 'break down stigma'
The mother of a teenager with type 1 diabetes says the latest addition to the Barbie range of dolls will help children understand more about the new doll was launched last week by Lila Moss, a 22-year-old model who has diabetes, as part of a drive to increase representation by toy manufacturer features a glucose monitor and insulin pump, along with a blue polka-dot top and skirt. The colour blue and circle print are used around the world to represent diabetes from Cleethorpes, whose 14-year-old son Will lives with the condition, said it was "breaking down the stigma" around diabetes. "Will for a long time didn't want a pod or a sensor because it was a visible thing that everybody would instantly know," Holly the latest addition to the Barbie range was a positive step, in a similar way to Barbie dolls that use wheelchairs, she added."It's inclusive and I think it's a good thing." Will said he was now quite used to managing his diabetes and having to "work out my carbs before I have stuff".Talking about the doll, he said it was "nice to be included", though when asked if he would play with one, he replied: "I don't think so."Will's younger sister, Alice, 8, said children who played with the doll "could pretend and maybe understand it and discover more about diabetes"."It's really important," she US toy giant had previously faced criticism that the traditional Barbie was not representative of most recent years, the firm has created dolls with a hearing aid, a prosthetic limb and a latest addition has also been welcomed by support groups and health Curtis, from the Hull and District Diabetes Support Group, who has lived with the condition himself for more than 30 years, said: "I think the idea of this doll is absolutely brilliant for Curtis said support and education were "essential", adding: "I think this is a great leap forward." Debbie Hicks, who developed the diabetes specialist nursing service in Hull, was diagnosed with type 1 diabetes in 1973, aged about its impact, she said: "Never knowing anybody with diabetes it was a complete shock for all of the family."It wasn't something we had ever come across – it was a total new way of life that both myself and my family had to adopt."You wouldn't believe that, at 12, I was using a glass syringe and needle that had to be sharpened once a week."Commenting on the doll, she said that although technology for managing the condition had greatly improved over the years, anything that helped to further raise awareness was very welcome. Listen to highlights from Lincolnshire on BBC Sounds, watch the latest episode of Look North or tell us about a story you think we should be covering here. Download the BBC News app from the App Store for iPhone and iPad or Google Play for Android devices
